these patients, perhaps because circulating antibody titers appear to decline with ongoing treatment. Disease progression has been noted in certain Anderson–Fabry disease patients on therapy, likely influenced…
progressive abnormalities, neurological (ataxia, intention tremor) and the variable irregularities in the immune system (progressive decrease in the number of T cells, the deficit of the major classes of immunoglobulins…
better understanding of the role of the immune response in the etiology and progression of PD is essential. During my talk, I will present original data about the impact ... GPER1). More recently, we successfully…
better understanding of the role of the immune response in the etiology and progression of PD is essential. During my talk, I will present original data about the impact ... GPER1). More recently, we successfully…
better understanding of the role of the immune response in the etiology and progression of PD is essential. During my talk, I will present original data about the impact ... GPER1). More recently, we successfully…
incidence of primary end point (cardiovascular/renal death, stroke, myocardial infarction, heart failure hospitalization, progressive renal insufficiency and permanent renal replacement therapy) did not differ…
involving 50 patients who were diagnosed with chronic rhino sinusitis. These patients were carefully selected excluding patients with coexisting comorbids including COPD, smokers. Results: Majority of patients included…
inorganic and organic drugs, such as treating a broad range of tumors and a selective mode of action. A promising examples, indazolium trans-[tetrachlorobis(1Hindazole) ruthenate(III)], auranofin ... where bipydmb-H =…
dysfunction, especially in the settings of hypertrophy and fibrosis. This is because, with progressive mural thickening, there is a dramatic increase in the deviation of the aggregates from their predominant ... than…
position paper that in all patients fulfilling the diagnostic criteria for clinically suspected myocarditis selective coronary angiography and EMB should performed. Any rational and specific therapeutic regimen for DCMi…
whom one pathomechanism was the sole or dominant cause of disease development and progression. Accordingly, future clinical trials are likely to increasingly focus upon patients in whom the high costs ... development…
histories were documented. Genomic DNA sample of the proband was subjected to exome sequencing (selected panel of 105 genes involved in retinal degeneration). Variants were analyzed for co-segregation amongst…
nano-material with anti-angiogenic activity and potential to deliver anticancer drug selectively to cancer cells may emerge as a promising therapeutic approach for treatment of cancer. Dendrimers represent…
been a step forward since pathological processes can be detected very early in progression of the disease. ■ Your research group performed the first PET scan of an amyloid plaque ... brain. At the Uppsala PET center the…
survival ranges between 12 and 18 months. The majority of patients suffer local tumor progression or recurrence, for which management is highly personalized, considering the patient’s clinical presentation, performance…
this nomenclature allows for uniformity in designing treatment volumes and is a prerequisite for progress in the development of radiation therapy. The increased conformality of modern radiotherapy planning techniques…
tumours. It has an innate ability to irradiate tumours with greater doses and spatial selectivity compared with electron and photon therapy and hence is a tissue sparing procedure. For more ... produce the particle…
Progress in the development of surrogate methods to evaluate the bioavailability and bioequivalence of drugs applied to the skin has resulted in the generation of a sufficient body of data ... potential limitation and…
high-throughput clone selection. Targeted integration into predetermined sites on the chromosome is a promising new area being explored. This review covers existing technology and recent progress made in improving
other behavioral abnormalities, and may comprise a distinctive appearance. In recent years, considerable progress has been reached in our understanding of the molecular pathophysiology and the impairment of…
therapies. In early development, their main use is to help select the best drugs and/or dosing regimens to progress in development. The case study demonstrates how a biomarker
durable responses. In addition to their complex side-effect profile, all patients eventually developed progressive disease and ultimately succumbed to their disease. Multiple clinical trials have addressed the…
clinical trials for PSC to date has demonstrated benefit in halting or slowing disease progression. Furthermore, the emerging recognition of several subtypes in PSC, coupled with limitations in histological ... explore…
diseases, inflammatory diseases of the joint and bowel, transplant rejection and multiple sclerosis. Significant progress over the last 30 years in the development of therapeutic mAbs has resulted in improved…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.